A U.S. Post-Approval Study of the PROMUS Element Plus Everolimus-Eluting Platinum Chromium Coronary Stent System
Phase of Trial: Phase IV
Latest Information Update: 02 Aug 2018
At a glance
- Drugs Everolimus (Primary) ; Aspirin; Clopidogrel; Prasugrel; Ticagrelor; Ticlopidine
- Indications Coronary disorders; Coronary stent thrombosis; Myocardial ischaemia
- Focus Therapeutic Use
- Acronyms PE Plus PAS
- Sponsors Boston Scientific Corporation
- 27 Jun 2018 Status changed from active, no longer recruiting to completed.
- 06 Mar 2018 Planned End Date changed from 1 Sep 2018 to 1 Jul 2018.
- 02 Nov 2017 4-Year Clinical Outcomes in PLATINUM-like patients from PE Plus PAS, PE PROVE and PLATINUM studies (n=1907) presented at the 29th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics